Moderna study shows covid-19 vaccine has potential for durable immunity

Moderna says that phase 1 covid-19 vaccine participants retained high levels of antibodies after 119 days.

The company sees 100m-125m doses available globally in Q1 of 2021 and  stated that the vaccine trial results consistent across all age groups.